Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Spotlight on Zoledronic Acid in the Management of Bone Metastases and Hypercalcemia of Malignancy

Spotlight on Zoledronic Acid in the Management of Bone Metastases and Hypercalcemia of Malignancy Zoledronic acid (Zometa®) is an effective inhibitor of osteoclast-mediated bone resorption. Zoledronic acid demonstrated efficacy in the reduction of skeletal-related events (SREs) in patients with multiple myeloma or bone metastases secondary to breast cancer, prostate cancer or other solid tumors, or hypercalcemia of malignancy. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Spotlight on Zoledronic Acid in the Management of Bone Metastases and Hypercalcemia of Malignancy

American Journal of Cancer , Volume 2 (3) – Aug 9, 2012

Loading next page...
 
/lp/springer-journals/spotlight-on-zoledronic-acid-in-the-management-of-bone-metastases-and-VLOC1JEpNn

References (29)

Publisher
Springer Journals
Copyright
Copyright © 2003 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200302030-00006
Publisher site
See Article on Publisher Site

Abstract

Zoledronic acid (Zometa®) is an effective inhibitor of osteoclast-mediated bone resorption. Zoledronic acid demonstrated efficacy in the reduction of skeletal-related events (SREs) in patients with multiple myeloma or bone metastases secondary to breast cancer, prostate cancer or other solid tumors, or hypercalcemia of malignancy.

Journal

American Journal of CancerSpringer Journals

Published: Aug 9, 2012

There are no references for this article.